H.C. Wainwright raised the firm’s price target on Ligand (LGND) to $206 from $157 and keeps a Buy rating on the shares based on upward adjustments to the firm’s Filspari sales projections after partner Travere (TVTX) announced that the FDA approved an update to the REMS labeling for the drug. The firm also cites adjustments to its underlying assumptions for Ligand’s later stage partnered assets.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: